Fülle H H, Hellriegel K P
Onkologie. 1986 Jun;9(3):152-3. doi: 10.1159/000215992.
10 patients with resistant or relapsed acute leukemia (9 AML, 1 ALL) were treated with idarubicin (4-demethoxydaunorubicin) in combination with cytosine arabinoside +/- etoposide. All patients had been heavily pretreated. 9 AML-patients had previously received 2-4 cycles of TAD-9 regimen. 2 complete and 1 partial remission were achieved. 1 patient died from septicemia in bone marrow aplasia without leukemic cells. 6 patients did not respond to idarubicin-based salvage treatment. The median survival from start of therapy was 4 months. Idarubicin-based combination chemotherapy is effective in relapsed acute leukemia, even in patients intensively pretreated with anthracyclines.
10例耐药或复发的急性白血病患者（9例急性髓系白血病，1例急性淋巴细胞白血病）接受了伊达比星（4-去甲氧柔红霉素）联合阿糖胞苷±依托泊苷治疗。所有患者均接受过大量预处理。9例急性髓系白血病患者此前接受过2 - 4个周期的TAD - 9方案治疗。获得2例完全缓解和1例部分缓解。1例患者死于骨髓再生障碍伴败血症，骨髓中无白血病细胞。6例患者对基于伊达比星的挽救治疗无反应。从治疗开始的中位生存期为4个月。基于伊达比星的联合化疗对复发的急性白血病有效，即使是接受过蒽环类药物强化预处理的患者。
